Activation of anti-oncogene P53 produced by embryonic extracts in "in vitro" tumor cells

Pier Mario Biava, Adriana Carluccio

Research output: Contribution to journalArticlepeer-review


It is clear from the literature that pregnant uteri extracts taken from C57BL/6 syngeneic mice during embryonic differentiation, such as Drosophila at blastodermic stage extracts, significantly inhibit the growth of Lewis tumor "in vivo". These results have been interpreted as a consequence of the regulation of genes involved in cell differentiation and apoptosis. In this study we examined the effects of embryonic extracts on different types of "in vitro" tumor cells: glioblastoma, hepatocarcinoma and melanoma. The activation of p53 antioncogene was evaluated after the administration of 100 microlitres of the following embryonic extracts: 1°) Zebrafish: a) middle blastula-gastrula, b) 5 somites, c) 20 somites; 2°) Trout: a) middle blastula-gastrula, b) 5 somites, c) 20 somites. The activation of P53 anti-oncogene was evaluated with immunohistochemical and analytical flow cytometry technique. We recorded a significant activation of P53 anti-oncogene after treatment with embryonic extracts. However, these effects were limited to certain types of embryonic extracts. We mapped the extracts which had the most significant effect on P53 anti-oncogene activation in glioblastoma cells. This study raises the possibility of further research on regulators present in the embryo during cell differentiation and seems to open up a way for the physiological control of malignancy.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalJournal of Tumor Marker Oncology
Issue number4
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Activation of anti-oncogene P53 produced by embryonic extracts in "in vitro" tumor cells'. Together they form a unique fingerprint.

Cite this